Be Ready for Questions About Molnupiravir to Treat COVID-19

January 2022

You’ll hear buzz about molnupiravir, an oral antiviral to treat COVID-19...now that it’s under FDA review.

Molnupiravir blocks viral replication by incorporating itself into the RNA of SARS-CoV-2...causing viral death.

It’s 4 capsules bid for 5 days...and seems well tolerated.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

COVID-19 Be Ready for Questions About Molnupiravir to Treat COVID-19
Ophthalmology Watch for Vuity, an Eye Drop to Improve Near Vision
Men's Health Compare Meds for Treating Benign Prostatic Hyperplasia
Stroke Think of the “ABCs” to Optimize Meds After a Stroke or TIA
End-of-Life Care Fine-Tune Meds in Hospice or Palliative Care Patients
Supplements Clarify the Role of Turmeric for COVID-19 and Other Uses
E-Cigarettes Explain What FDA Authorization of E-Cigarettes Really Means
Hematology/Oncology Be Familiar With Nuances of Prostate Cancer Meds
Antipsychotics Stay Alert for Lybalvi, a New Combo Antipsychotic
Seizures Evaluate the Need for Seizure Prophylaxis
Antifungals Determine Who May Benefit From Empiric Antifungals